NASDAQ:GNMX - Aevi Genomic Medicine Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.84 -0.13 (-13.40 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$0.97
Today's Range$0.83 - $0.98
52-Week Range$0.83 - $2.65
Volume239,700 shs
Average Volume155,120 shs
Market Capitalization$57.71 million
P/E Ratio-1.01
Dividend YieldN/A
Beta1.12
Aevi Genomic Medicine logoAevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive GNMX News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GNMX
CUSIPN/A
Phone610-254-4201

Debt

Debt-to-Equity RatioN/A
Current Ratio5.78
Quick Ratio5.78

Price-To-Earnings

Trailing P/E Ratio-1.01
Forward P/E Ratio-1.40
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.52 per share
Price / Book1.62

Profitability

EPS (Most Recent Fiscal Year)($0.83)
Net Income$-34,710,000.00
Net MarginsN/A
Return on Equity-160.09%
Return on Assets-127.64%

Miscellaneous

Employees17
Outstanding Shares59,340,000
Market Cap$57.71

The Truth About Cryptocurrencies

Aevi Genomic Medicine (NASDAQ:GNMX) Frequently Asked Questions

What is Aevi Genomic Medicine's stock symbol?

Aevi Genomic Medicine trades on the NASDAQ under the ticker symbol "GNMX."

How were Aevi Genomic Medicine's earnings last quarter?

Aevi Genomic Medicine Inc (NASDAQ:GNMX) issued its earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01. View Aevi Genomic Medicine's Earnings History.

What price target have analysts set for GNMX?

2 analysts have issued twelve-month price targets for Aevi Genomic Medicine's shares. Their predictions range from $1.50 to $7.00. On average, they anticipate Aevi Genomic Medicine's share price to reach $4.25 in the next twelve months. This suggests a possible upside of 406.0% from the stock's current price. View Analyst Ratings for Aevi Genomic Medicine.

What is the consensus analysts' recommendation for Aevi Genomic Medicine?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aevi Genomic Medicine in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Aevi Genomic Medicine's key competitors?

Who are Aevi Genomic Medicine's key executives?

Aevi Genomic Medicine's management team includes the folowing people:
  • Mr. Michael F. Cola, CEO, Pres & Director (Age 58)
  • Mr. Brian D. Piper, CFO & Corp. Sec. (Age 46)
  • Dr. Garry A. Neil, Chief Scientific Officer (Age 64)
  • Ms. Colleen Anderson, VP of Clinical Operations
  • Dr. Rick Couch, VP of Chemistry, Manufacturing & Controls

Has Aevi Genomic Medicine been receiving favorable news coverage?

News stories about GNMX stock have been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aevi Genomic Medicine earned a news impact score of 0.09 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 45.62 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Aevi Genomic Medicine?

Shares of GNMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aevi Genomic Medicine's stock price today?

One share of GNMX stock can currently be purchased for approximately $0.84.

How big of a company is Aevi Genomic Medicine?

Aevi Genomic Medicine has a market capitalization of $57.71 million. The biotechnology company earns $-34,710,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Aevi Genomic Medicine employs 17 workers across the globe.

How can I contact Aevi Genomic Medicine?

Aevi Genomic Medicine's mailing address is 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087. The biotechnology company can be reached via phone at 610-254-4201 or via email at [email protected]


MarketBeat Community Rating for Aevi Genomic Medicine (NASDAQ GNMX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  107 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Aevi Genomic Medicine and other stocks. Vote "Outperform" if you believe GNMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.